Polycystic Kidney Disease
Originally approved for hyponatremia, the medication is the first FDA-approved treatment for rapidly progressing autosomal dominant polycystic kidney disease in adults.
A summary of Dr. Ronald D. Perrone's presentation that will be given at the National Kidney Foundation's 2016 Spring Clinical Meetings in Boston, MA.
ERA-EDTA offers guidance on selecting patients for treatment, when to start the drug, dosing strategies, and other aspects of care.
In a study, the arrhythmia was 31% more likely to occur in PKD patients than non-PKD control patients.
New findings suggest the medication induces beneficial renal structural changes.
Analysis of data from the HALT PKD trial showed that 0% to 0.4% of patients experienced potassium levels above 6.5 mEq/L.
After 3 weeks of treatment, total kidney volume decreased and urine volume increased.
Review examines etiology of disease and suggests stepwise approach for pain management.
Tight blood pressure control slows the rate of increase in total kidney volume and reduces left ventricular index.
This approach resulted in improved hypertension control in patients with autosomal dominant polycystic kidney disease, new study found.
Patients are more likely to receive a kidney transplant and less likely to die than patients with end-stage renal disease from other causes.
In a small study, researchers performed the procedure using N-butyl cyanoacrylate.
The dietary flavonoid naringenin has been found to regulate the PKD2 protein responsible for polycystic kidney disease.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)